Antagonism of opioid receptors reduces body fat in obese rats by decreasing food intake and stimulating lipid utilization

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 284, Issue 6 53-6, 2003, Pages

  Statnick, Michael A ^a   Tinsley, Frank C ^a   Eastwood, Brian J ^a   Suter, Todd M ^a   Mitch, Charles H ^a   Heiman, Mark L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Body composition; Dual energy X ray absorptiometry; Ex vivo receptor binding; Indirect calorimetry; Respiratory quotient

Indexed keywords

3,4 DIMETHYL 4 (3 HYDROXYPHENYL)PIPERIDINE; OPIATE ANTAGONIST; OPIATE RECEPTOR; UNCLASSIFIED DRUG; CYCLOHEXANE DERIVATIVE; LY 243670; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY FAT; BODY MASS; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FOOD INTAKE; LIPID METABOLISM; MALE; NEUROMODULATION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; ADIPOSE TISSUE; ANIMAL; BODY COMPOSITION; CALORIC INTAKE; CELL RESPIRATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENERGY METABOLISM; FEEDING BEHAVIOR; LONG EVANS RAT; METABOLISM;

ADIPOSE TISSUE; ANIMALS; BODY COMPOSITION; CELL RESPIRATION; CYCLOHEXANES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENERGY INTAKE; ENERGY METABOLISM; FEEDING BEHAVIOR; LIPID METABOLISM; MALE; OBESITY; PIPERIDINES; RATS; RATS, LONG-EVANS; RECEPTORS, OPIOID;

EID: 0038515754     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.00632.2002     Document Type: Article

References (47)

1. Apfelbaum M and Mandenoff A. Naltrexone suppresses hyperphagia induced in the rat by a highly palatable diet. Pharmacol Biochem Behav 15: 89-91, 1981.
2. Atkinson RL. Naloxone decreases food intake in obese humans. J Clin Endocrinol Metab 55: 196-198, 1982.
3. Atkinson RL, Berke LK, Drake CR, Bibbs ML, and Williams FLDL. Effects of long-term therapy with naltrexone on body weight in obesity. Clin Pharmacol Ther 38: 419-422, 1985.
4. Carr KD. Feeding, drug abuse, and the sensitization of reward by metabolic need. Neurochem Res 21: 1455-1467, 1996.
5. Chen Y and Heiman ML. Chronic leptin administration promotes lipid utilization until fat mass is greatly reduced and preserves lean mass of normal female rats. Regul Pept 92: 113-119, 2000.
6. Chua SC, Brown AW, Hennessey KJ, Leibel RL, and Hirsch J. Food deprivation and hypothalamic neuropeptide gene expression: effects of strain background and the diabetes mutation. Brain Res Mol Brain Res 11: 291-299, 1991.
7. Cohen MR, Cohen RM, Pickar D, and Murphy DL. Naloxone reduces food intake in humans. Psychosom Med 47: 132-138, 1985.
8. Elia M and Livesey G. Energy expenditure and fuel selection in biological systems: the theory and practice of calculations based on indirect calorimetry and tracer methods. World Rev Nutr Diet 70: 68-131, 1992.
9. Ferguson-Segall M, Flynn JJ, Walker J, and Margules DL. Increased immunoreactive dynorphin and Leu-enkephalin in posterior pituitary of obese mice (oh/oh) and supersensitivity to drugs that act at kappa receptors. Life Sci 31: 2233-2236, 1982.
10. Flatt JP. Assessment of daily and cumulative carbohydrate and fat balances in mice. J Nutr Biochem 2: 193-202, 1991.
11. Glass MJ, Billington CJ, and Levine AS. Opioids and food intake: distributed functional neural pathways? Neuropeptides 33:360-368, 1999.
12. Glass MJ, Grace M, Cleary JP, Billington CJ, and Levine AS. Potency of naloxone's anorectic effect in rats is dependent on diet preference. Am J Physiol Regul Integr Comp Physiol 271: R217-R221, 1996.
13. Hagan MM, Rushing PA, Benoit SC, Woods SC, and Seeley RJ. Opioid receptor involvement in the effect of AgRP-(83-132) on food intake and food selection. Am J Physiol Regul Integr Comp Physiol 280: R814-R821, 2001.
14. Herve C and Fellmann D. Changes in rat melanin-concentrating hormone and dynorphin messenger ribonucleic acids induced by food deprivation. Neuropeptides 31: 237-242, 1997.
15. Hoebel BG. Brain neurotransmitters in food and drug reward. Am J Clin Nutr 42: 1133-1150, 1985.
16. Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, and Wiegand SJ. Ciliary neurotrophic factor activates leptin-Like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Natl Acad Sci USA 98: 4652-4657, 2001.
17. Levine AS, Grace M, Billington CJ, and Zimmerman DM. Central administration of the opioid antagonist, LY255582, decreases short- and long-term food intake in rats. Brain Res 566: 193-197, 1991.
18. Malcolm R, O'Neil PM, Sexauer JD, Riddle FE, Currey HS, and Counts C. A controlled trial of naltrexone in obese humans. Int J Obes 9: 347-353, 1985.
19. Mandenoff A, Fumeron F, Apfelbaum M, and Margules DL. Endogenous opiates and energy balance. Science 215: 1536-1538, 1982.
20. Mann PE, Pasternak GW, Hahn EF, Curreri G, and Lubin ER. Comparison of effects of chronic administration of naloxone and naloxonazine upon food intake and maintenance of body weight in rats. Neuropharmacology 27: 349-355, 1988.
21. Margules DL, Moisset B, Lewis MJ, Shibuya H, and Pert CB. β-Endorphin is associated with overeating in genetically obese mice (ob/ob) and rats (fa/fa). Science 202: 988-991, 1978.
22. Marks-Kaufman R, Balmagiya T, and Gross E. Modifications in food intake and energy metabolism in rats as a function of chronic naltrexone infusions. Pharmacol Biochem Behav 20: 911-916, 1984.
23. Martin WR, Wikler A, Eades CG, and Pescor FT. Tolerance to and physical dependence on morphine in rats. Psychopharmacologia 4: 247-260, 1963.
24. McKinzie JH, Emmerson PJ, Suter TM, Surface P, Mitch C, and Statnick MA. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines exhibit sodium dependent opioid receptor binding and inverse agonism. Soc Neurosci Abstr 27: 310.12, 2001.
25. Mitch CH, Leander JD, Mendelsohn LG, Shaw WN, Wong DT, Cantrell BE, Johnson BG, Reel JK, Snoddy JD, Takemori AE, and Zimmerman D. 3,4-Dimethyl-4-(3-hydroxyphenyl)piperidines: opioid antagonists with potent anorectant activity. J Med Chem 36: 2842-2850, 1993.
26. Mitchell JE, Morley JE, Levine AS, Hatsukami D, Gannon M, and Pfohl D. High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychol 22: 35-42, 1987.
27. Morrison DF. Multivariate Statistical Methods (2nd ed.). New York: McGraw-Hill, 1976, p. 205-215.
28. Olson GA, DeLatte SW, Kastin AJ, McLean JH, Phillpott DR, and Olson RD. Naloxone and fluid consumption in rats: dose response relationship for 15 days. Pharmacol Biochem Behav 23: 1065-1068, 1985.
29. Olszewski PK, Wirth MM, Grace MK, Levine AS, and Giraudo SQ. Evidence of interactions between melanocortin and opioid systems in regulation of feeding. Neuroreport 12: 1727-1730, 2001.
30. Ostrowski NL, Rowland NE, Foley TL, Nelson JL, and Reid LD. Morphine antagonists and consummatory behavior. Pharmacol Biochem Behav 14: 549-559, 1981.
31. Pierroz DD, Ziotopoulou M, Ungsunan L, Moschos S, Flier JS, and Mantzoros CS. Effects of acute and chronic administration of the melanocortin agonist MTII in mice with diet-induced obesity. Diabetes 51: 1337-1345, 2002.
32. Pfeiffer DG, Nikolarakis KE, and Pfeiffer A. Chronic blockade of opiate receptors: influence on reproduction and body weight in female rats. Neuropeptides 5: 279-282, 1984.
33. Recant L, Voyles NR, Luciano M, and Pert CB. Naltrexone reduces weight gain, alters "β-endorphin," and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1: 309-313, 1980.
34. Reid LD. Endogenous opioid peptides and regulation of drinking and feeding. Am J Clin Nutr 42: 1099-1132, 1985.
35. Rose BS, Flatt WP, Martin RJ, and Lewis RD. Whole body composition of rats determined by dual energy X-ray absorptiometry is correlated with chemical analysis. J Nutr 128: 246-250, 1998.
36. Roth JD and Rowland NE. Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats. Psychopharmacology 137: 99-106, 1998.
37. 2B (enkephalin-sensitive) binding site. Peptides 14: 17-20, 1993.
38. Shaw WN. Long-term treatment of obese Zucker rats with LY255582 and other appetite suppressants. Pharmacol Biochem Behav 46: 653-659, 1993.
39. Shaw WN, Mitch CH, Leander JD, Mendelsohn LG, and Zimmerman DM. The effect of the opioid antagonist LY255582 on body weight of the obese Zucker rat. Int J Obes 15: 387-395, 1991.
40. Spiegel TA, Stunkard AJ, Shrager EE, O'Brien CP, Morrison MF, and Stellar E. Effect of naltrexone on food intake, hunger, and satiety in obese men. Physiol Behav 40: 135-141, 1987.
41. Statnick MA, Suter TM, Gackenheimer SL, Emmerson PJ, Quimby SJ, Gehlert DR, Wheeler WJ, and Mitch CH. Sodium dependent high affinity binding of 3H-LY515300, a 3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid receptor inverse agonist. Eur J Pharmacol In press.
42. Swanson SP, Catlow J, Pohland RC, Chay SH, and Johnson T. Disposition of the opioid antagonist, LY255582, in rats and dogs. Drug Metab Dispos 23: 916-921, 1995.
43. Trenchard E and Silverstone T. Naloxone reduces the food intake of normal human volunteers. Appetite 4: 43-50, 1983.
44. Welch CC, Kim EM, Grace MK, Billington CJ, and Levine AS. Palatability-induced hyperphagia increases hypothalamic Dynorphin peptide and mRNA levels. Brain Res 721: 126-131, 1996.
45. Wolkowitz OM, Doran AR, Cohen MR, Cohen RM, Wise TN, and Pickar D. Effect of naloxone on food consumption in obesity. N Engl J Med 313: 327, 1985.
46. Yeomans MR, Wright P, Macleod HA, and Critchley JAJH. Effects of nalmefene on feeding in humans: dissociation of hunger and palatability. Psychopharmacology 100: 426-432, 1990.
47. Zimmerman DM, Leander JD, Cantrell BE, Reel JK, Snoddy J, Mendelsohn LG, Johnson BG, and Mitch CH. Structure-activity relationships of trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine antagonists for mu- and kappa-opioid receptors. J Med Chem 36: 2833-2841, 1993.